ecotropic viral integration site 2AGenealiases: EVDA · EVI-2A · EVI2
Q-omics provides the consensus-scored EVI2A profile across patient tissues and cancer cell-line models. EVI2A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, EVI2A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, EVI2A RNA expression shows 18,220 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where EVI2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EVI2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EVI2A survival associations across molecular data types. EVI2A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EVI2A RNA expression–survival associations across cancer types. High EVI2A expression shows unfavorable associations in UVM and LUSC, but favorable associations in SKCM, HNSC, CESC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for EVI2A RNA expression.
This table summarizes EVI2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for EVI2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EVI2A shows lower tumor expression in COAD, LUSC and LUAD and higher tumor expression in KIRC, KIRP and BRCA. The KIRC box plot shows higher EVI2A RNA expression in tumor versus normal tissue (log2 FC = +2.320, t-test p < 0.001).
This table shows molecular features associated with EVI2A in patient tissues and cancer cell lines. In patient samples, EVI2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, EVI2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
